BRAF and colonic neoplasm: Supporting previous findings that BRAF-V600E colon tumors are resistant to treatment with vemurafenib,19Smad4f/f; BrafV600E/+ organoids were not sensitive to vemurafenib alone, or to treatment with erlotinib (Figs 4A and 4B).